NanoBio: First Patients Vaccinated In Phase 1B Nasal Flu Vaccine Study
Building upon a series of successful preclinical and clinical studies, Ann Arbor-based NanoBio Corp. Tuesday announced the initiation of a second tolerability and immunogenicity study designed to test and further optimize its novel nanoemulsion-based intranasal vaccine adjuvant.
